Cargando…

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results

Detalles Bibliográficos
Autores principales:	Hughes, T P, Leber, B, Cervantes, F, Spector, N, Pasquini, R, Clementino, N C D, Schwarer, A P, Dorlhiac-Llacer, P E, Mahon, F-X, Rea, D, Guerci-Bresler, A, Kamel-Reid, S, Bendit, I, Acharya, S, Glynos, T, Dalal, D, Branford, S, Lipton, J H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668492/ https://www.ncbi.nlm.nih.gov/pubmed/28862704 http://dx.doi.org/10.1038/leu.2017.247

Ejemplares similares

α-bisabolol Is an Effective Proapoptotic Agent against BCR-ABL(+) Cells in Synergism with Imatinib and Nilotinib
por: Bonifacio, Massimiliano, et al.
Publicado: (2012)

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
por: Weisberg, E, et al.
Publicado: (2006)

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
por: Hochhaus, A, et al.
Publicado: (2016)

Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
por: Weisberg, E, et al.
Publicado: (2019)

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
por: Pouwer, Marianne G., et al.
Publicado: (2018)

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
por: Stein, Andrew M, et al.
Publicado: (2013)

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
por: Kaur, Pavinder, et al.
Publicado: (2007)

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
por: Cauchi, C., et al.
Publicado: (2011)

Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib
por: Oruganti, Baswanth, et al.
Publicado: (2022)

BCR::ABL1 transcripts and clinical outcome ‐ interrogating the technique
por: Branford, Susan
Publicado: (2022)

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia
por: Pagani, Ilaria S., et al.
Publicado: (2018)

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
por: Kantarjian, Hagop M., et al.
Publicado: (2021)

The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation
por: Conchon, Monika, et al.
Publicado: (2009)

Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice
por: Santoleri, Fiorenzo, et al.
Publicado: (2013)

Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib
por: Stacchiotti, Silvia, et al.
Publicado: (2013)

Effects of imatinib and nilotinib on the whole transcriptome of cultured murine osteoblasts
por: Kirschner, Gyöngyi, et al.
Publicado: (2016)

BCR-ABL V280G Mutation, Potential Role in Imatinib Resistance: First Case Report
por: Azevedo, Ana P, et al.
Publicado: (2017)

Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular response
por: Machado, Melissa Pereira, et al.
Publicado: (2011)

The Proteolytic Activity of Separase in BCR-ABL-Positive Cells Is Increased by Imatinib
por: Haaß, Wiltrud, et al.
Publicado: (2012)

Identification of Drug Combinations Containing Imatinib for Treatment of BCR-ABL+ Leukemias
por: Kang, Yunyi, et al.
Publicado: (2014)

Initial Rate of BCR::ABL1 Decline for Response Prediction in Chronic Myeloid Leukemia
por: Branford, Susan
Publicado: (2022)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna(®)) with the human ABC drug transporter P-glycoprotein
por: Shukla, Suneet, et al.
Publicado: (2014)

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
por: Mesa, Ruben A
Publicado: (2007)

Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia
por: Sun, Xiaoyan, et al.
Publicado: (2016)

Using healthcare claims data to analyze the prevalence of BCR‐ABL‐positive chronic myeloid leukemia in France: A nationwide population‐based study
por: Foulon, Stéphanie, et al.
Publicado: (2019)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
por: Uz, B., et al.
Publicado: (2011)

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
por: Swords, Ronan, et al.
Publicado: (2009)

Nilotinib Is More Potent than Imatinib for Treating Plexiform Neurofibroma In Vitro and In Vivo
por: Wei, Jiang, et al.
Publicado: (2014)

Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib
por: Kim, T-M, et al.
Publicado: (2011)

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
por: Quentmeier, Hilmar, et al.
Publicado: (2011)

Inhibition of BCR/ABL Protein Expression by miR-203 Sensitizes for Imatinib Mesylate
por: Li, Yajuan, et al.
Publicado: (2013)

AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax
por: Low, Soon Khai, et al.
Publicado: (2022)

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis
por: Hochhaus, Andreas, et al.
Publicado: (2017)

Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling
por: Frolov, Antonina, et al.
Publicado: (2016)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
por: Lan, Xiaoying, et al.
Publicado: (2016)

A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway
por: Wei, Liuya, et al.
Publicado: (2020)

Molecular Requirements for the Expression of Antiplatelet Effects by Synthetic Structural Optimized Analogues of the Anticancer Drugs Imatinib and Nilotinib
por: Pantazi, Despoina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ojgmfv5pr674a2orlfubrbou2i